1	DEBRA W. YANG	
2	United States Attorney LEON W. WEIDMAN	
3	Assistant United States Attorney Chief, Civil Division VINCE FARHAT	
4	Assistant United States Attorney California Bar Number 183794	4
5	Room 7516, Federal Building 300 North Los Angeles Street	
6	Los Angeles, California 900 Telephone: (213)894-2400	
7	Facsimile: (213)894-7819	
8	PETER D. KEISLER Assistant Attorney General	
9	Civil Division RICHARD N. GOLDBERG	
10	Trial Attorney United States Department of Just:	ice
11	1331 Pennsylvania Avenue, N. Suite 950 North	
12	Washington, D.C. 20004	
13	Telephone: (202)307-2532 Facsimile: (202)514-8742	
14	Attorneys for Plaintiff United States of America	
15		
16	UNITED STATES	DISTRICT COURT
17	FOR THE CENTRAL DIS	TRICT OF CALIFORNIA
18	WESTERN	DIVISION
19	UNITED STATES OF AMERICA,	No. CV 03-4670 GAF (AJWx)
20	Plaintiff,	AMENDED COMPLAINT FOR CIVIL
21	ν.	PENALTIES, INJUNCTIVE AND OTHER RELIEF
22	LISA LEVEY, in her capacity as	
23	personal representative of the Estate of MICHAEL LEVEY;	
24	GARY BALLEN; BENTLEY MYERS INTERNATIONAL	
25	CO.; PUBLISHER'S DATA SERVICES, INC.; and	
26	NUTRITIONAL LIFE, INC.,	
27	Defendants.	
28		

1		TABLE OF CONTENTS
2	I.	Jurisdiction and Venue
3	II.	Defendants
4	III.	Prior Commission Proceeding 6
5	IV.	Course of Conduct
6		A. Zymax
7		B. Millenex <u>es</u>
8		C. Serotril
9		D. Cartazyne <u>ds</u>
10	V.	Violations of the FTC Order
11		First Cause of Action
12		Second Cause of Action
13		Third Cause of Action
14		Fourth Cause of Action
15		Fifth Cause of Action
16		Sixth Cause of Action
17		Seventh Cause of Action
18		Eighth Cause of Action
19	VI.	Violations of the FTC Act
20		Ninth Cause of Action
21		Tenth Cause of Action
22		Eleventh Cause of Action
23	VII.	Consumer Injury
24	VIII	Civil Penalties, Redress, Injunctive and
25		Other Equitable Relief
26	IX.	Prayer for Relief
27	Inde	x of Exhibits
28		

Plaintiff, United States of America, acting upon notification and authorization to the Attorney General by the Federal Trade Commission ("Commission" or "FTC"), for its Complaint alleges that:

5 Plaintiff brings this action under Sections 5(a), 5(1), 1. 6 12, 13(b), and 16(a) of the Federal Trade Commission Act ("FTC 7 Act"), 15 U.S.C. §§ 45(a), $45(\underline{1})$, 52, 53(b), and 56(a): (a) to obtain monetary civil penalties, consumer redress, injunctive and 8 9 other relief from defendants Lisa Levey, in her capacity as 10 personal representative of the Estate of Michael Levey, Bentley Myers International Co., Publisher's Data Services, Inc., and 11 12 Nutritional Life, Inc., for violations of a final order to cease 13 and desist issued by the Commission; and (b) to obtain injunctive, redress and other relief for Michael Levey's, Gary 14 15 Ballen's, Bentley Myers International Co.'s, Publisher's Data 16 Services, Inc.'s, and Nutritional Life, Inc.'s unfair or 17 deceptive acts and practices and false advertising in violation 18 of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 19 52.

20

I. JURISDICTION AND VENUE

21 2. This Court has jurisdiction over this matter pursuant
22 to 15 U.S.C. §§ 45(a), 45(<u>1</u>), 52, 53(b), and 56(a) and under 28
23 U.S.C. §§ 1331, 1337, 1345, and 1355.

3. Venue in the Central District of California is proper
under 15 U.S.C. § 53(b) and under 28 U.S.C. §§ 1391(b-c) and
1395(a).

27

28

II. DEFENDANTS

4. Defendant Lisa Levey is the representative of the

-3-

Estate of Michael Levey. Before his death on August 2, 2003, 1 2 Michael Levey ("Levey") was the president and co-owner of 3 defendant Bentley Myers International Co., and co-owner of defendant Publisher's Data Services, Inc. Individually or in 4 5 concert with others, Levey formulated, directed, controlled, or participated in the acts and practices of defendants Bentley 6 Myers International Co., Publisher's Data Services, Inc., and 7 Nutritional Life, Inc. (collectively, "the corporate 8 9 defendants"), including the acts and practices set forth in this 10 Complaint, and did so at all times pertinent to this action. 11 Levey resided and transacted business in the Central District of 12 California.

Defendant Gary Ballen ("Ballen") is a director and co-13 5. 14 owner of defendant Bentley Myers International Co., president and 15 co-owner of defendant Publisher's Data Services, Inc., and owner of defendant Nutritional Life, Inc. Individually or in concert 16 17 with others, Ballen formulates, directs, controls, or 18 participates in the acts and practices of the corporate 19 defendants, including the acts and practices set forth in this 20 Complaint, and has done so at all times pertinent to this action. 21 He resides and transacts or has transacted business in the 22 Central District of California.

6. Defendant Bentley Myers International Co. ("Bentley
Myers") is a Nova Scotia, Canada, corporation that was
incorporated in 1998, and was registered in British Columbia,
Canada, that year. Bentley Myers' office and principal place of
business in Canada is located at 203-2780 Granville Street,
Vancouver, British Columbia, Canada. Its registered office is

-4-

1 located at 1050-1188 West Georgia Street, Vancouver, British 2 Columbia, Canada. Bentley Myers is engaged in the marketing, 3 promotion and sale of dietary supplements and other health-4 related products to U.S. consumers via direct mail solicitations 5 and telephone orders. Bentley Myers transacts or has transacted 6 business in the Central District of California and throughout the 7 United States.

7. Defendant Publisher's Data Services, Inc. ("Publisher's
Data") is a California corporation that was incorporated in 1998.
Its principal place of business is 9090 Burton Way, Suite 201,
Beverly Hills, California 90211. Publisher's Data provides data
and information processing services, including telephone support
services, to Bentley Myers. Publisher's Data transacts or has
transacted business in the Central District of California.

15 8. Defendant Nutritional Life, Inc. ("Nutritional Life"), 16 is or was a California corporation that was incorporated in 1981. 17 Its principal place of business is 9350 Civic Center Drive, Suite 18 140, Beverly Hills, California 90210. Although Nutritional 19 Life's corporate status is or was suspended in California, Levey, 20 Ballen, Bentley Myers and Publisher's Data continued to transact 21 business in this name, including contracting with a third-party credit card processor that facilitates the transfer of funds 22 23 among the various credit card organizations and Levey, Ballen, 24 Bentley Myers and Publisher's Data for credit card sales to consumers. Nutritional Life transacts or has transacted business 25 in the Central District of California. 26

27 9. Levey, Ballen and the corporate defendants have28 operated together as a common enterprise to manufacture,

-5-

1 advertise, package, label, promote, offer for sale, sell or 2 distribute dietary supplements and other health-related products 3 to consumers throughout the United States, in or affecting 4 commerce, as "commerce" is defined in Section 4 of the FTC Act, 5 15 U.S.C. § 44.

6 Either singly or in connection with one or more members 10. 7 of the common enterprise, Levey, Ballen and the corporate defendants also have done business under various names, 8 including, but not limited to, Denman Scientific Research, 9 10 Cartazyne Sciences International, Serotril Sciences 11 International, Arthritis and Joint Disease Center, Nutritional 12 Fulfillment Center, Vancouver Natural Products, Vancouver Health 13 Products, and NLI Gentin.

14

III. PRIOR COMMISSION PROCEEDING

15 11. In a Commission proceeding bearing Docket No. C-3459, 16 the Commission's complaint charged Levey, in part, with 17 disseminating, or causing to be disseminated, false or misleading 18 television advertisements for the EuroTrym Diet Patch, the Foliplexx baldness product, and the Y-Bron impotence treatment, 19 20 and for performing deceptive demonstrations during infomercials 21 he produced for the Magic Wand hand mixer. Ballen appeared in 22 Levey's advertisements as an endorser of the Y-Bron product. The 23 Commission charged that Levey's practices constituted unfair or 24 deceptive acts or practices, and the making of false advertisements in or affecting commerce, in violation of Sections 25 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52. 26

27 12. On September 23, 1993, the Commission issued a Decision
28 and Order ("FTC Order") against Levey, individually and as an

-6-

officer of Positive Response Marketing, Inc., and against 1 Positive Response Marketing, Inc., also doing business as 2 Positive Response Television and Positive Response Advertising, 3 to cease and desist certain advertising and marketing practices. 4 The FTC Order was served upon Levey in the Fall of 1993, and by 5 operation of law, became final and enforceable thereafter. The 6 FTC Order has remained in full force and effect ever since. 7 Copies of the Commission's complaint and the FTC Order are 8 9 attached hereto as Exhibits A and B, respectively. Pursuant to 10 the requirements set forth in Part XI of the FTC Order, copies of 11 the FTC Order were distributed to, among others, Levey. At all 12 times relevant to the counts of this Complaint, Levey and the 13 corporate defendants knew of the FTC Order.

14 13. The Commission's Order includes the following 15 provisions:

ORDER

DEFINITIONS

18 For purposes of this Order:

16

17

19

20

21

22

23

24

25

26

27

28

1) "Competent and reliable scientific evidence" shall mean tests, analyses, research, studies or other evidence based on the expertise of professionals in the relevant area, that has been conducted and evaluated in an objective manner by persons qualified to do so, using procedures generally accepted in the profession to yield accurate and reliable results.

* * *

-7-

1 II. 2 IT IS FURTHER ORDERED that respondent Positive 3 Response Marketing, Inc., a corporation, its successors and assigns, and its officers, and respondent Michael 4 5 S. Levey, individually and as an officer of said 6 corporation, and respondents' agents, representatives 7 and employees, directly or through any partnership, 8 corporation, subsidiary, division or other device, do 9 forthwith cease and desist from: 10 11 в. Representing, directly or by implication, in 12 connection with the advertising, packaging, 13 labeling, promotion, offering for sale, sale 14 or distribution of any other product in or 15 affecting commerce, as "commerce" is defined 16 in the Federal Trade Commission Act, that: 17 (1) Use of the product prevents or reduces 18 feelings of hunger; 19 Use of the product enables users to lose (2) 20 substantial amounts of weight; 21 Use of the product enables users to lose (3) 22 weight in a substantial number of cases; 23 or 24 (4) Any competent or reliable test or study 25 establishes that use of the product 26 promotes weight loss, 27 unless such representation is true and, at the 28 time of making such representation, respondents

-8-

possess and rely upon competent and reliable scientific evidence that substantiates the representation.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

* *

VI.

IT IS FURTHER ORDERED that respondent Positive Response Marketing, Inc., a corporation, its successors and assigns, and its officers, and respondent Michael S. Levey, individually and as an officer of said corporation, and respondents' agents, representatives and employees, directly or through any partnership, corporation, subsidiary, division or other device, in connection with the advertising, packaging, labeling, promotion, offering for sale, sale or distribution of any product or service in or affecting commerce, as "commerce" is defined in the Federal Trade Commission Act, do forthwith cease and desist from:

A. Making any representation, in any manner, directly or by implication, regarding the efficacy or safety of any food, drug or device, as those terms are defined in Section 15 of the Federal Trade Commission Act, 15 U.S.C. § 55, unless at the time of making such representation respondents possess and rely upon competent and reliable scientific evidence that substantiates the representation; provided, however, that any such representation for any food product that

-9-

is specifically permitted in labeling for such food product by regulations promulgated by the Food and Drug Administration pursuant to the Nutrition Labeling and Education Act of 1990 will be deemed to be substantiated by competent and reliable scientific evidence; provided further that any such representation for any over-the-counter drug product in Final Regulations establishing conditions under which such product is safe and effective promulgated by the Food, Drug and Cosmetic Act, will be deemed to be substantiated by competent and reliable scientific evidence.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

B. Making any representation, in any manner, directly or by implication, regarding the performance, benefits, efficacy or safety of any product or service (other than a representation covered under Subpart VI.A above), unless at the time of making such representation respondents possess and rely upon competent and reliable evidence, which when appropriate must be competent and reliable scientific evidence, that substantiates the representation.

VII.

IT IS FURTHER ORDERED that respondent Positive Response Marketing, Inc., a corporation, its successors

-10-

and assigns, and its officers, and respondent Michael S. Levey, individually and as an officer of said corporation, and respondents' agents, representatives and employees, directly or through any partnership, corporation, subsidiary, division or other device, in connection with the advertising, packaging, labeling, promotion, offering for sale, sale or distribution of any product or service in or affecting commerce, as "commerce" is defined in the Federal Trade Commission Act, do forthwith cease and desist from:

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

* * *

- C. Representing, in any manner, directly or by implication, by words, depictions or symbols, that such product or service has been endorsed by a person, group or organization that is an expert with respect to the endorsement message unless:
 - (1) The endorser is an existing person, group or organization whose qualifications give it the expertise that the endorser is represented as possessing with respect to the endorsement; and
 - (2) The endorsement is supported by an objective and valid evaluation or test using procedures generally accepted by experts in that science or profession to yield accurate and reliable results.

-11-

IT IS FURTHER ORDERED that respondent Positive Response Marketing, Inc., a corporation, its successors and assigns, and its officers, and respondent Michael S. Levey, individually and as an officer of said corporation, and respondents' agents, representatives and employees, directly or through any partnership, corporation, subsidiary, division or other device, in connection with the advertising, packaging, labeling, promotion, offering for sale, sale or distribution of any product or service in or affecting commerce, as "commerce" is defined in the Federal Trade Commission Act, in connection with any advertisement depicting a demonstration, experiment or test, do forthwith cease and desist from making any representation, in any manner, directly or by implication, that any demonstration, picture, experiment or test depicted in the advertisement proves, demonstrates or confirms any material quality, feature or merit of any product, when such demonstration, picture, experiment or test does not prove, demonstrate or confirm the representation for any reason, including but not limited to:

VTTT.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

- A. The undisclosed use or substitution of a material mock-up or prop.
- B. The undisclosed material alteration in a material characteristic of the advertised product or any other material prop or device depicted in the advertisement.

-12-

C. The use of a visual perspective or camera, film, audio or video technique that, in the context of the advertisement as a whole, materially misrepresents a material characteristic of the advertised product or any other material aspect of the demonstration.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

* * *

XII.

IT IS FURTHER ORDERED that respondent Michael S. Levey shall, for a period of ten (10) years from the date of issuance of this Order, notify the Commission within thirty (30) days of the discontinuance of his present business or employment and of his affiliation with any new business or employment. Each notice of affiliation with any new business or employment shall include the respondent's new business address and telephone number, current home address, and a statement describing the nature of the business or employment and his duties and responsibilities.

IV. COURSE OF CONDUCT

14. Since at least 1998, Levey, Ballen and the corporate defendants have manufactured, advertised, packaged, labeled, promoted, offered for sale, sold or distributed numerous dietary supplements and other health-related products. Their products have included, but are not limited to, the following, each of which is a "food" or "drug" within the meaning of Sections 12 and 15 of the FTC Act, 15 U.S.C. §§ 52 and 55:

-13-

a. Zymax, a weight loss product containing the ingredient Ma Huang (the herb Ephedra sinica, also known as Chinese Ephedra, which contains ephedrine alkaloids commonly referred to as ephedra). For example, Levey, Ballen and the corporate defendants have offered a thirty-day supply of Zymax for \$29.95 and a ninety-day supply of Zymax for \$79.95. The label lists a daily dose of two pills with each pill containing 7.5 mg of ephedrine.

1

2

3

4

5

6

7

8

9

17

18

19

20

21

22

23

24

25

26

27

28

- b. MillenexES, another weight loss product containing the
 ingredient Ma Huang. For example, Levey, Ballen and
 the corporate defendants have offered a thirty-day
 supply of MillenexES for \$29.95 and a ninety-day supply
 of MillenexES for \$79.95. The label lists a daily dose
 of two pills with each pill containing 7.5 mg of
 ephedrine.
 - c. Serotril, a product containing hypericum perforatum (the herb commonly known as St. John's wort) that Levey, Ballen and the corporate defendants have marketed for weight loss. For example, Levey, Ballen and the corporate defendants have offered a thirty-day supply of Serotril for \$29.95 and a ninety-day supply of Serotril for \$89.95.
 - d. Cartazyne<u>DS</u>, an oral arthritis treatment combining glucosamine sulfate and chondroitin sulfate. For example, Levey, Ballen and the corporate defendants have offered a thirty-day supply of Cartazyne<u>DS</u> for \$29.95 and a ninety-day supply of Cartazyne<u>DS</u> for

-14-

\$79.95.

1

23

2 15. Levey's, Ballen's and the corporate defendants' 3 marketing efforts have included glossy, multi-page brochures mailed to millions of consumers in the United States. Depending 4 upon the product, Levey, Ballen and the corporate defendants have 5 used a different name ("d/b/a") in their brochures. For example, 6 7 Levey, Ballen and the corporate defendants have used the d/b/a8 "Denman Scientific Research" in promotional materials for Zymax, 9 the d/b/a "Cartazyne Sciences International" in promotional 10 materials for CartazyneDS, and the d/b/a "Serotril Sciences, 11 International" in promotional materials for Serotril. These 12 advertisements solicit consumers to: (a) mail order forms and 13 checks, credit card numbers, or money orders to a Vancouver, Canada address; (b) fax in their order forms to an "international 14 15 fax" number; or (c) call a toll-free number to order the desired 16 products. The various toll-free telephone numbers listed in 17 Levey's, Ballen's and the corporate defendants' promotional 18 materials ring to telephones located within the United States.

19 16. As set forth below, Levey, Ballen and the corporate
20 defendants have made numerous misleading or unsubstantiated
21 claims about the products in violation of the FTC Order and
22 Sections 5(a) and 12(a) of the FTC Act.

A. Zymax

17. Levey, Ballen and the corporate defendants have disseminated or have caused to be disseminated advertisements and promotional materials for Zymax, including, but not necessarily limited to, brochures titled "Plastic Surgery Magazine" attached hereto as Exhibits C-1, C-2, and C-3, which contain the following

-15-

statements, among others: 1

2

3

4

5

6

7

8

9

11

15

16

17

18

19

20

21

22

23

24

25

26

27

28

a. "I thought I would never be able to lose this weight. I went from a size 14 down to a sexy size 6. My friends think I had plastic surgery. They're very jealous!"

> (Quotation is adjacent to photo of woman) (Exhibit C-1, March 2002 edition of "Plastic Surgery Magazine," p. 131; Exhibit C-2, February-March 2001 edition of "Plastic Surgery Magazine," p. 143)

10 "This powerful formula attacks weight loss in a unique b. and extremely effective manner. We recognize that 12 unsightly fat deposits are usually very hard to get rid 13 of. Our goal was to make it as simple and as foolproof 14 as possible-almost automatic!"

"After much hard work, we were finally able to safely increase thermogenesis and quickly promote weight loss*," Dr. Perry energetically added. "Patients actually enjoy taking Zymax for two reasons: It gives you loads of energy for work, play and exercise, plus you lose lots of weight while you still eat!"

*These statements have not been evaluated by the Food & Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. (Text and quotations are adjacent to photo of man in white physician's coat and stethoscope, with caption "Dr. David Perry, MD") (Exhibit C-1, p. 132; Exhibit C-

-16-

1		2, p. 144)
2	c.	"Doctors & Scientists Discover Amazing New Fat Burning
3		Breakthrough"
4		"Subject: Female 155 lbs"
5		"Individual results will naturally vary"
6		(Text is adjacent to photos of three unclothed
7		backsides pictured side by side. The three backsides
8		are progressively thinner from left to right, and bear
9		the labels "Baseline Reference," "Mid-Test Reference,"
10		and "Final Observation," respectively) (Exhibit C-1, p.
11		132; Exhibit C-2, p. 144, which does not include
12		"Individual results will naturally vary.")
13	d.	Clinical Studies Show How ZymaX Finally Ends Useless
14		Dieting!
15		(Exhibit C-1, p. 134; Exhibit C-2, p. 146)
16	e.	ZymaX Actually <u>Increases</u> In Effectiveness The Longer
17		You Take It!
18		(Exhibit C-1, p. 135, headline; Exhibit C-2, p. 147,
19		headline)
20	f.	We decided to ask a registered pharmacist, B. Bubman,
21		to review the Zymax formula and studies, and compare
22		Dr. Perry's new formula to the blur of bottles and
23		boxes that line drugstore shelves. Below are his
24		personal findings and his comments.
25		
26		
27		
28		

I

Product		Comments
Zymax	•••	Natural, safe, effective.
		Clinically tested, with
		guaranteed results.
Metabolite	•••	Expensive. Sold thru
		distributors who mark up price
		for big profit. Can make you
		jittery. Expensive!
Dexatrim	•••	Synthetic OTC drug. Common
		appetite suppressant. Comes with
		low cal diet. Side effects.
Accutrim	•••	Synthetic OTC drug. Common
		appetite suppressant. Comes with
		low cal diet. Side-effects.
Slim-Fast	•••	Powdered meal replacement drink.
		Comes with low-cal diet. Uses
		artificial sweeteners.
Xenical	•••	Synthetic prescription drug. Car
		cause runny & uncontrollable
		bowel movements.
Meridia	• • •	Synthetic prescription drug.
		Expensive appetite suppressant.
		Has side-effects & can cause
		chemical addiction!
(Exhibit C-1	, p. 13	6; Exhibit C-2, p. 148)
"Zymax is sc	much m	ore than I ever expected. I went
		e 6 in a very short time-and kept
		m still full of energy and loving
	- -· -	

-18-

life!"

(Exhibit C-1, p. 137; Exhibit C-2, p. 149)

h.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Dear Denman Scientific Research Customer Service:

I apologize for being so skeptical when I called and asked if Zymax really works. Your representative, Lily, was so pleasant and patient with me. You see, I had been 60 pounds overweight for most of my adult life and embarrassed to leave my house at times. I had tried so many other diet pills and all I lost was more self-image and more money. I hope you understand why I asked so many questions now.

I am writing this letter to let you know that Zymax worked great for me. Each morning when I got on my bathroom scale, the weight loss was obvious-but even more impressive was when I looked in the mirror! I could actually see myself getting thinner everyday! I am almost at my goal weight and ready to switch to the Zymax maintenance program.

. . . Best of all, it's been months now and my weight is staying down, and I still have lots of energy. . . .

Thanks, Love Alice Wilcox, New York, NY (Exhibit C-1, p. 138; Exhibit C-2, p. 150) i. SAFE AND EFFECTIVE ZYMAX IS AVAILABLE WITHOUT A PRESCRIPTION

* * *

"I woke up in the morning one full dress size smaller!"

* * *

1		Amazing Success of New Fat Burning Formula Now
2		CONFIRMED By 8 Major Clinical Tests
3		(Exhibit C-2, p. 153)
4	j.	WARNING Losing weight is extremely easy with new
5		Zymax. It is important that you set a target weight
6		before you begin the Zymax program.
7		Do Not Lose Too Much Weight
8		Weigh yourself often when using Zymax. As your weight
9		begins to plummet, reduce your dose and follow the
10		Zymax maintenance instructions. Please look at the
11		chart to the right and identify your ideal weight prior
12		to taking Zymax.
13		Being too thin can be just as dangerous as being
14		overweight!
15		(Text is adjacent to chart of height and weigh)
16		(Exhibit C-3, February 2000 edition of "Plastic Surgery
17		Magazine," p. 163)
18	k.	Below are the most frequently asked questions received
19		by the Denman Scientific Research consultants, and
20		answers provided by their medical and professional
21		staff.
22		Q: "I have tried those appetite suppressants that you
23		can buy in stores and they really don't work for me.
24		Why will Zymax work when I've failed with so many other
25		methods to lose weight?
26		A: This is one of the most frequently asked
27		questions Zymax works by naturally increasing
28		thermogenesis and directing your body to use stubborn

-20-

stored fat as energy. The result is a flood of new 1 2 energy plus weight loss you can count on. You're not alone-many of those in the clinical studies also had 3 failed using other methods, and were quite surprised at 4 5 how easy it was to lose weight quickly with Zymax. 6 7 "How much and how fast will I lose weight with 0: 8 Zymax? Is there a diet you have to follow?" 9 Since results naturally vary, this is a difficult A: 10 question to accurately answer. Weight loss often 11 begins in about 48-hours after taking Zymax and then 12 accelerates over the next few days to a week. You 13 should set a target weight prior to starting Zymax. As 14 your weight begins to plummet, switch to the Phase 2 15 dose, explained in the instruction booklet. Losing too 16 much weight can be just as unhealthy as being 17 overweight! There is absolutely no fad, starvation 18 diet to follow. 19 (Exhibit C-2, p. 151) 20 1. SAFE & EFFECTIVE ZYMAX NOW AVAILABLE WITHOUT A 21 PRESCRIPTION! 22 (Exhibit C-2, p. 153; Exhibit C-3, p. 165) 23 18. Levey's, Ballen's and the corporate defendants' advertisements, in numerous instances, do not refer to ephedra or 24 25 ephedrine and instead include "other ECA stack components" in 26 fine print as one of many ingredients. (Exhibit C-2, p. 150; 27 Exhibit C-3, p. 162). ECA stands for "ephedra, caffeine and 28 aspirin."

-21-

1 In numerous instances when ordering Zymax by telephone, 19. 2 consumers who asked Levey's, Ballen's and the corporate 3 defendants' customer service representatives about the risks associated with Zymax have been told that the product is natural, 4 safe, and without side effects. Ephedra, however, can have side 5 effects, such as jitteriness and increased blood pressure. 6 In 7 addition, the risk of side effects due to ingestion of ephedra increases with increased dosage. 8

B. MillenexES

9

19

20

21

22

23

24

25

26

27

28

10 20. Levey, Ballen and the corporate defendants have 11 disseminated or have caused to be disseminated advertisements and 12 promotional materials for MillenexES, including, but not 13 necessarily limited to, the brochure titled "Diet News" attached 14 hereto as Exhibit D, which contains the following statements, 15 among others:

16 a. "I lost 38 pounds and found more romance than I ever 17 thought possible. I'm loving life now!" "This Pill is 18 Amazing!"

(Exhibit D, Summer 2001 edition of "Diet News," p. 167)b. New Safe Fat-Fighting Pill

* * *

Dr. [Robert] Aldan and his team had been searching for an effective way to lower life-threatening serum triglyceride and cholesterol levels, when they made the discovery that made them the talk of the entertainment world - at least behind the scenes. "The discovery of Millenex<u>ES</u> (*Mill-in-ex Extra Strength*) was actually an accident. Honest!"

-22-

1		* * *
2		Weight Loss Has Never Been So Easy
3		Now, for the first time, here's a clinically proven,
4		dynamic approach that's both fast and very effective
5		
6		"The Millenex <u>ES</u> formula also contains a group of
7		natural ingredients that boost your energy level
8		without giving you the jitters.* Having plenty of
9		energy and a strong feeling of well-being is important
10		when losing weight," added Dr. Aldan. "You can feel
11		Millenex <u>ES</u> working. You actually feel good while
12		losing!"
13		* * *
14		*These statements have not been evaluated by the Food $\&$
15		Drug Administration. This product is not intended to
16		diagnose, treat, cure or prevent any disease.
17		(Exhibit D, p. 168)
18	C.	Virtually Automatic Weight Loss
19		[Dr. Aldan explains:] " Best of all, weight
20		loss can begin automatically."
21		(Exhibit D, p. 169)
22	d.	No Will Power? NO PROBLEM! Millenex <u>ES</u> Lets You Eat
23		Without Feeling Guilty
24		* * *
25		"I wanted to eat what \underline{I} want to eat, without the fat
26		sticking to my hips and thighs! That's why I tried
27		Millenex <u>ES</u> . It's amazing!"
28		* * *

"The MillenexES system works at a cellular level and prevents fat from being digested and then stored in all the wrong places.*" Dr. Aldan continues, "You should never have to crash diet again. MillenexES can become a part of your life. This dietary supplement formula is safe, even for prolonged use, when used according to instructions.["]

* * *

*These statements have not been evaluated by the Food & Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. (Exhibit D, p. 172)

e. Dear Dr. Aldan:

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

22

24

25

26

27

28

I was fat in high school. I was fat all through college. . . I'm writing this letter today with a smile on my face after just getting off my bathroom scale. Since I started the Millenex<u>ES</u> system, I've lost 39 pounds! This is amazing! I still enjoy most of the foods I love, and the weight just kept melting off. . . .

21 Thank you,

Stacy Delmonica (TV actress)

23 Hey Doc!

I took you up on your offer to try Millenex<u>ES</u> and I have to say it performed exactly as stated. . . . After just a few weeks on Millenex<u>ES</u>, I've lost 55 pounds! . . . Thank you for this weight loss miracle! Mr. Don Jeffreys & Randy

(Exhibit D, p. 175) 1 2 f. MillenexES Lets YOU Decide How Much Weight You Want To 3 Lose 4 What's your weight loss goal? 5 Go ahead, set your goal. Save this page and look back 6 at it 7 at it in a month after you start on the MillenexES 8 system. 9 You'll be pleasantly surprised! 10 10 pounds 11 20 pounds 12 40 pounds 13 50 pounds 14 80 pounds + 15 (Exhibit D, p. 175) 16 We never thought a little pill could promote such fast q. 17 and effortless weight loss. Before we knew it, I lost 18 28 pounds and Jim lost 43 pounds and we're full of 19 energy. We never had to follow any stupid diet. 20 This MillenexES is really going to catch on. Best of 21 all, it's safe! What a winner! Keep up the good work, 22 Doc. - Jim and Betty Wilson 23 (Exhibit D, p. 177) 24 21. Levey's, Ballen's and the corporate defendants' 25 advertisements, in numerous instances, do not refer to ephedra or ephedrine and instead includes "ECA" in very small type as just 26 27 one ingredient among a long list of "Fat Modulators." (Exhibit D, 28 p. 173)

-25-

C. Serotril

1		<u>C. Serotril</u>
2	22.	Levey, Ballen and the corporate defendants have
3	diss	eminated or have caused to be disseminated
4	adve	rtisements and promotional materials for Serotril,
5	incl	uding, but not necessarily limited to, brochures titled
6	"Ser	otril Sciences" attached hereto as Exhibits E-1 through
7	E-3,	which contain the following statements, among others:
8	a.	Serotril A and Serotril B: Next, as part of the
9		Serotril System you'll take Serotril A and B daily.
10		These are not magic, miracle pills. Rather, these are
11		pharmaceutical grade supplements which have some pretty
12		amazing properties.
13		(Exhibit E-1, "Special Edition" of "Serotril Sciences"
14		Vol 3 - No. 5, p. 181)
15	b.	Now losing weight is so easy!
16		PLUS - New formulas that really make a difference.
17		(Exhibit E-1, p. 193)
18	c.	Many medical researchers and professionals contributed
19		to the formulation of the two natural components,
20		Serotril A and Serotril B. As mentioned in the special
21		announcement you received, the main ingredient in
22		Serotril A (High Grade Hypericum Perforataum) has been
23		studied and found to be beneficial for naturally
24		stimulating serotonin production
25		* * *
26		Follow the simple rules and you will lose weight.
27		There is no question about it you will lose weight
28		with Serotril It's safe, natural, healthy <u>and</u>

1		<u>it</u> works.
2		(Exhibit E-2, Winter/Spring 1999 edition of "Serotril
3		Sciences" Vol 2 - No. 4, p. 201)
4	d.	Barbara lost 36 lbs Dr. J. lost 48 lbs.
5		(Text is immediately below photos) (Exhibit E-2, p.
6		203; Exhibit E-3, Serotril brochure, p. 213)
7	e.	Overweight Person:
8		Always Hungry, Depressed, Low Energy, Sad.
9		Abnormally Low Serotonin Level
10		(Text is immediately above line graph showing dramatic
11		changes in "Serotonin level," frequently dropping below
12		and rising above a line labeled "Hunger Stimulation
13		Point (Must Eat)")
14		Above: Female, 42 years old, 48 lbs. overweight. Has
15		tried 8 different starvation diets, 3 prescription
16		drugs, intensive exercise with little or no
17		improvement
18		Below: Same person after 28 days on natural Serotril.
19		Lost 19 lbs. so far. Looks noticeably younger. Happy,
20		energetic again!
21		After Using Serotril 1 Month
22		Automatically losing weight daily. Happy & Energetic!
23		Normal Daily Serotonin Cycle
24		(Text is immediately above second line graph, showing
25		constant "Serotonin level," never dropping below a line
26		labeled "Hunger Stimulation Point (Must Eat)").
27		(Exhibit E-2, p. 203; Exhibit E-3, p. 213)
28	f.	Serotril contains a delicate, small molecule that has

some very amazing properties. For years this natural miracle has been used in Europe and was proven safe.

* * *

Serotril naturally stimulates the production of serotonin, causing spontaneous weight loss without useless dieting! Since Serotril is <u>not</u> a drug, there are no unpleasant side effects, even with prolonged usage.

People report losing weight quickly with Serotril. Even though Serotril is so effective, it's <u>not</u> a drug! This new breakthrough is now available, and <u>without</u> a doctor's prescription (though you should always check with your doctor before starting this or any other weight loss regimen).

(Exhibit E-2, p. 204)

g. The most exciting part of Dr. [Jean-Paul] Rappaport's discovery is that Serotril is really a "Wellness Formula." Though users are thrilled about their rapid and effortless weight loss, Serotril is also providing many other critically important health benefits. Like most, this reporter is most anxious to use Serotril for its weight-loss benefits. (After all, if Serotril is being used by TV stars and is natural, why not give it a try?) However, as Dr. Rappaport explained, there is much more to his discovery than just easy weight loss. Wellness! (Exhibit E-2, p. 205)

h. Dear Reader:

I am proud of the team of scientists in France and 1 2 Canada that have worked to perfect the Serotril system. 3 This is truly a long awaited breakthrough. . . . My formula does not contain ephedrine, caffeine or any 4 5 drug stimulants. Serotril is 100% natural and safe. 6 The extremely clean and pure natural elements we 7 discovered in Canada and Europe contribute to the 8 quality and success of the Serotril formula. 9 Your Friend, - Dr. Jean-Paul Rappaport 10 (Text is adjacent to photo of man in business attire 11 leaning on desk, with caption "Jean-Paul Rappaport, MD, 12 Paris, France") (Exhibit E-2, p. 206) 13 i. "Stars panic when they're getting ready to attend award shows like TV's Golden Globe because they must look 14 15 their best, " calmly explained Dr. Jean-Paul Rappaport. 16 "They know that my natural weight loss formula, 17 Serotril, works without dieting and without side 18 effects that might affect their performances and 19 careers." 20 (Text is adjacent to photo of man, with caption "Dr. 21 Jean Paul-Rappaport, France") (Exhibit E-3, p. 208) 22 New Natural "Super" Pill --j. 23 The biggest break-through for weight-loss since the 24 scale! 25 Plus, Drug Company's FEN-PHEN coverup revealed (See p. 26 5). 27 "When you correct the biochemical cause of weight gain, 28 you can lose weight effortlessly, without dieting

-29-

. . . 312-435-5544 george." (See p. 9)

(Exhibit E-3, p. 207)

1

2

3

D. CartazyneDS

4	23.	Levey, Ballen and the corr	porate defendants have
5	dissemina	ted or have caused to be d	isseminated advertisements and
6	promotion	al materials for Cartazyne <u>I</u>	<u>DS</u> , including, but not
7	necessari	ly limited to, brochures t	itled "Longevity Sciences
8	Report" a	ttached hereto as Exhibits	F-1 and F-2, which contain
9	the follo	wing statements and depict	ions, among others:
10	a.	Rare, Natural Formula <u>Floo</u>	ods Painful Joints With
11		Soothing Lubricants	
12		Doctor's New, Tiny "Super	Pill" May Actually
13		Eliminate Agonizing Joint	Pain In Just Days
14		Amazing Compound Called Th	ne " <u>Cure</u> " For Arthritis!
15		(Exhibit F-1, Cartazyne <u>DS</u>	brochure, p. 222)
16	b.	The PAIN of Arthritis	Healthy! - <u>NO</u> <u>More Pain!</u>
17		Doctor's Observation	Doctor's Observation
18		✓ Joints Swollen & Red	Joints Healthy!
19		✓ Gross Deformities	Normal Size Again!
20		✓ Cracking Cartilage	Cartilage Healthy!
21		✓ SEVERE PAIN	NO PAIN!
22		(Text in left column refer	rs to picture of arthritic
23		hand and arthritic hand x-	-ray; Text in right column
24		refers to picture of healt	thy hand and healthy hand x-
25		ray) (Exhibit F-1, p. 222))
26	C.	Beverly Hills Doctor Disco	overs Solution to Common
27		Arthritis Pain	
28		Natural combination of ess	sential ingredients actually

-30-

1		helps rebuild new cartilage.
2		* * *
3		Arthritis Sufferer Shares Her Agonizing Pain & Plea for
4		Cure
5		She was skeptical at first, but discovers a new life
6		when her joint pain completely ended.
7		(Exhibit F-1, p. 223)
8	d.	It Can Stop Arthritis Pain & Send New Cartilage to
9		Joints Within Days
10		Available Now Without a Prescription
11		* * *
12		Dr. Leonard Rapoport, Board Certified surgeon, has for
13		years prescribed what is now called " <i>Cartazyne<u>DS</u></i> "
14		(cart-a-zeen, <u>D</u> ouble <u>S</u> trength) to his patients, friends
15		and family who suffer from joint pain caused by
16		osteoarthritis, the most common form of arthritis. The
17		results have been miraculous. Within days, pain stops
18		and new, healthy cartilage begins to develop.
19		(Text is adjacent to photo of man in white physician's
20		coat and stethoscope pointing to vertebrae model, with
21		caption "Dr. Leonard Rapoport, Beverly Hills
22		Homeopathic Healthcare.") (Exhibit F-1, p. 224)
23		
24		
25		
26		
27		
28		

1	e.	Cartazyne <u>DS</u> Rebuilds	Cartilage Naturally
2		"It's like WD-40 i	
3		In Just A Few D	ays Your Joint
4		Pain Could <u>I</u>	<u>End</u> Forever
5		Before CartazyneDS	Normal & Pain Free
6		Excess synovial fluid	Perfect fluid level
7		buildup causing	
8		tightness, discomfort	
9		inflammation &	
10		shooting <u>PAIN</u>	
11			
12		Subchronal bone	Healthy Cartilage providing
13		breaking down causing	cushion to bone - Completely
14		grinding and PAIN	PAIN FREE movement
15			
16		Worn & deteriorating	Good circulation
17		cartilage (cushion)	
18		- <u>PAIN!</u>	
19		(Text in left column re	fers to picture of arthritic
20		shoulder; Text in right	column refers to picture of
21		healthy shoulder) (Exhi	bit F-1, p. 225)
22		* *	*
23		"Cartazyne <u>DS</u> , a complet	ely natural approach, addresses
24		the arthritis affected	cartilage and bone itself,"
25		explains Dr. Rapoport.	"You <u>can</u> actually begin to re-
26		grow new, healthy, smoo	th cartilage. Movement <u>can</u>
27		become fluid and pain f	ree again. It doesn't just
28		cover-up joint pain, it	gets to the cause - <u>once and</u>
	1		

-32-

1		for all! That's the miracle."
2		(Exhibit F-1, p. 225)
3	f.	As a surgeon, Dr. Rapoport cautions those
4		considering hip, knee and other joint replacement
5		. ["]I always recommend addressing joint pain first
6		with Cartazyne <u>DS</u> before considering surgery. The
7		formula is completely drug free and without side
8		effects. It is vital that doctors begin recognizing
9		natural treatments."
10		Joint Replacement Draw Backs
11		Temporary
12		Very Painful
13		Costly
14		Questionable success rate
15		No risk or side effects with natural, drug free:
16		Cartazyne <u>DS</u> (Double Strength)
17		Natural, Safe & Effective!
18		(Exhibit F-1, p. 228)
19	g.	[Dr. Rapoport's] research and understanding of the
20		usage of natural remedies has presented his patients
21		with options seldom offered by most physicians.
22		Cartazyne <u>DS</u> is just one of Dr. Rapoport's many
23		commendable achievements.
24		(Exhibit F-1, p. 231)
25	h.	My Dear friend:
26		Even if you've suffered from arthritis pain for
27		years, Cartazyne <u>DS</u> provides precious resources so your
28		body can rebuild cartilage and reduce painful

-33-

inflammation in a very short time. There is no doubt about it. Cartazyne<u>DS</u> works! . . . Cartazyne Sciences is a division of Bentley-Myers International of Vancouver, Canada. My role as Medical Director of Bentley-Myers is to insure that you are receiving the highest quality of pharmaceutical grade ingredients in all our formulas. My team is also responsible for monitoring worldwide research involving natural products that can improve your health and raise your quality of life.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

You are holding our latest catalog of international discoveries. Each of these formulas have gone through rigorous clinical studies. Only after my department has thoroughly reviewed these tests, do we release these formulas to you.

We have carefully developed these formulas to deliver benefits without side effects common with prescription drugs. I personally use many of these products daily and hope you too will take advantage of all that nature has to offer through these proven formulas. . . . Thank you,

Leonard Rapoport, M.D., F.A.C.S.

(Exhibit F-2, "Longevity Sciences Report" Vol. 3 No. 4, p. 234)

1 V. VIOLATIONS OF THE FTC ORDER 2 FIRST CAUSE OF ACTION Violation of FTC Order - Unsubstantiated No Side Effects Claims 3 4 for Zymax and MillenexES 5 (against Levey, Bentley Myers, Publisher's Data, 6 and Nutritional Life) 7 24. Through the means described in Paragraphs 17 through 21, Levey and the corporate defendants, in connection with the 8 9 manufacturing, advertising, packaging, labeling, promotion, 10 offering for sale, sale or distribution of Zymax and MillenexES, 11 on numerous occasions, have represented, expressly or by 12 implication, that: 13 a. Zymax, containing Ma Huang, or ephedra, has no side 14 effects; and 15 b. MillenexES, containing Ma Huang, or ephedra, has no side effects. 16 17 25. The representations set forth in Paragraph 24 were not 18 substantiated at the time the representations were made. 19 Therefore, Levey, Bentley Myers, Publisher's Data, and 20 Nutritional Life have made the representations set forth in 21 Paragraph 24 in violation of Part VI.A of the FTC Order. 22 SECOND CAUSE OF ACTION 23 Violation of FTC Order - False or Unsubstantiated Weight Loss 24 Claims for Zymax and MillenexES 25 (against Levey, Bentley Myers, Publisher's Data, 26 and Nutritional Life) 27 26. Through the means described in Paragraphs 17 and 20, 28 Levey and the corporate defendants, in connection with the

1 manufacturing, advertising, packaging, labeling, promotion, 2 offering for sale, sale or distribution of Zymax and MillenexES, 3 on numerous occasions, have represented, expressly or by 4 implication, that:

- 5 a. Zymax enables users to lose substantial amounts of 6 weight in a short period of time without the need to 7 increase exercise or reduce caloric intake, enabling 8 users, for example, to go from a size 14 or 12 to a 9 size 6; and
- b. Millenex<u>ES</u> enables users to lose substantial amounts of
 weight in a short period of time without the need to
 increase exercise or reduce caloric intake, enabling
 users, for example, to lose 30 to 50 pounds or more.
- 14 27. The representations set forth in Paragraph 26 are false 15 or were not substantiated at the time the representations were 16 made. Therefore, Levey, Bentley Myers, Publisher's Data, and 17 Nutritional Life have made the representations set forth in 18 Paragraph 26 in violation of Parts II.B and VI.A of the FTC 19 Order.

THIRD CAUSE OF ACTION

20

23

24

21 Violation of FTC Order - Unsubstantiated Clinical Study Claims
 22 for Zymax and Millenex<u>ES</u>

(against Levey, Bentley Myers, Publisher's Data, and Nutritional Life)

28. Through the means described in Paragraphs 17 and 20,
26 Levey and the corporate defendants, in connection with the
27 manufacturing, advertising, packaging, labeling, promotion,
28 offering for sale, sale or distribution of Zymax and MillenexES,

1 on numerous occasions, have represented, expressly or by 2 implication, that:

7

8

9

10

16

17

18

19

20

- a. Clinical studies prove that Zymax enables users to lose
 substantial amounts of weight in a short period of time
 without the need to increase exercise or reduce caloric
 intake; and
 - b. Clinical studies prove that Millenex<u>ES</u> enables users to lose substantial amounts of weight in a short period of time without the need to increase exercise or reduce caloric intake.

29. The representations set forth in Paragraph 28 were not
 substantiated at the time the representations were made.
 Therefore, Levey, Bentley Myers, Publisher's Data, and
 Nutritional Life have made the representations set forth in
 Paragraph 28 in violation of Part VI.A of the FTC Order.

FOURTH CAUSE OF ACTION

Violation of FTC Order - False or Unsubstantiated Weight Loss Claims for Serotril

(against Levey, Bentley Myers, Publisher's Data,

and Nutritional Life)

21 30. Through the means described in Paragraph 22, Levey and 22 the corporate defendants, in connection with the manufacturing, 23 advertising, packaging, labeling, promotion, offering for sale, sale or distribution of Serotril, on numerous occasions, have 24 25 represented, expressly or by implication, that Serotril enables 26 users to lose substantial amounts of weight in a short period of 27 time without the need to increase exercise or reduce caloric 28 intake.

1 31. The representation set forth in Paragraph 30 is false 2 or was not substantiated at the time the representations were 3 made. Therefore, Levey, Bentley Myers, Publisher's Data, and 4 Nutritional Life have made the representation set forth in 5 Paragraph 30 in violation of Parts II.B and VI.A of the FTC 6 Order.

7

8

9

10

19

20

21

22

23

FIFTH CAUSE OF ACTION

Violation of FTC Order - Fictitious Experts (against Levey, Bentley Myers, Publisher's Data, and Nutritional Life)

11 32. Through the means described in Paragraphs 17, 20, and 12 22, Levey and the corporate defendants, in connection with the 13 manufacturing, advertising, packaging, labeling, promotion, 14 offering for sale, sale or distribution of Zymax, MillenexES, and 15 Serotril, on numerous occasions, have represented, expressly or 16 by implication, that such products have been endorsed by "Dr. 17 David Perry, " "Dr. Jean-Paul Rappaport, " and "Dr. Robert Aldan." 18 33. In fact:

- a. "Dr. David Perry," "Dr. Jean-Paul Rappaport," and "Dr. Robert Aldan" are fictitious persons and thus are not existing persons whose qualifications give them the expertise that they are represented as possessing with respect to the endorsement; and
- b. These fictitious persons' endorsements, pertaining to
 the efficacy and the lack of side effects of Zymax,
 MillenexES, and Serotril, are not supported by an
 objective and valid evaluation or test using procedures
 generally accepted by experts in that science or

-38-

profession to yield accurate and reliable results. 1 2 34. Therefore, Levey, Bentley Myers, Publisher's Data, and Nutritional Life have made the representations set forth in 3 Paragraph 32 in violation of Part VII.C. of the FTC Order. 4 5 SIXTH CAUSE OF ACTION 6 Violation of FTC Order - Unsubstantiated Efficacy Claims for 7 Cartazyne<u>DS</u> 8 (against Levey, Bentley Myers, Publisher's Data, 9 and Nutritional Life) 10 Through the means described in Paragraph 23, Levey and 35. 11 the corporate defendants, in connection with the manufacturing, 12 advertising, packaging, labeling, promotion, offering for sale, 13 sale or distribution of CartazyneDS, on numerous occasions, have 14 represented, expressly or by implication, that: 15 CartazyneDS cures arthritis; a. 16 CartazyneDS rebuilds cartilage in human joints within b. 17 days; and 18 CartazyneDS is an effective alternative to joint c. 19 replacement surgery. 20 The representations set forth in Paragraph 35 were not 36. 21 substantiated at the time the representations were made. 22 Therefore, Levey, Bentley Myers, Publisher's Data, and 23 Nutritional Life have made the representations set forth in 24 Paragraph 35 in violation of Part VI.A of the FTC Order. 25 26 27 28 -39-

1						
1 2		SEVENTH CAUSE OF ACTION				
2		Violation of FTC Order - False Demonstrations for Zymax and				
		Cartazyne <u>DS</u>				
4	(against Levey, Bentley Myers, Publisher's Data,					
5	and Nutritional Life)					
6 7						
7	Levey and the corporate defendants, in connection with the					
8	manufacturing, advertising, packaging, labeling, promotion,					
9		offering for sale, sale or distribution of Zymax and Cartazyne <u>DS</u> ,				
10	on numerous occasions, have represented, expressly or by					
11						
12		ter" photographs or				
13	13 visual images of a person's unclothe	d backside depicted				
14	14 in advertisements for Zymax accurate	ly represent the				
15	15 performance of Zymax in causing subs	tantial weight				
16	16 loss; and					
17	17 b. That the results shown in "before/af	ter" pictures,				
18	18 medical illustrations, and other vis	ual images,				
19	19 including x-ray film, depicted in th	e advertisements				
20	20 for Cartazyne <u>DS</u> accurately represent	the performance of				
21	21 Cartazyne <u>DS</u> on human joints.					
22	22 38. The representations set forth in Par	agraph 37 are				
23	23 false. Therefore, Levey, Bentley Myers, Publi	sher's Data, and				
24	24 Nutritional Life have made the representations	set forth in				
25	25 Paragraph 37 in violation of Part VIII of the	FTC Order.				
26	26					
27	27					
28	28					
	-40-					

EIGHTH CAUSE OF ACTION

Violation of FTC Order - Failure to Notify FTC of New Business Affiliation

(against Levey)

5 39. After the FTC Order became final in 1993, Levey became 6 an owner, officer, employee, and/or consultant for defendants 7 Bentley Myers and Publishers' Data some time prior to 2001. By a 8 letter dated May 8, 2001, from his attorney, Levey provided 9 written notice to the FTC of his affiliation with Bentley Myers 10 and Publishers' Data.

11 40. Levey failed to notify the Commission within thirty 12 (30) days of his affiliation with the new business or employment, 13 <u>i.e.</u>, that he became an owner, officer, employee, and/or 14 consultant for defendants Bentley Myers and Publishers' Data, 15 thereby violating Part XII of the FTC Order.

16

1

2

3

4

VI. VIOLATIONS OF THE FTC ACT

17 41. Section 5(a) of the FTC Act, 15 U.S.C. § 45(a), 18 prohibits unfair or deceptive acts or practices in or affecting 19 commerce. Section 12(a) of the FTC Act, 15 U.S.C. § 52(a), 20 prohibits the dissemination of any false advertisement in or 21 affecting commerce for the purpose of inducing, or which is 22 likely to induce, the purchase of food, drugs, devices, or 23 cosmetics. For the purposes of Section 12 of the FTC Act, 15 24 U.S.C. § 52, Zymax, MillenexES, Serotril, and CartazyneDS are each either a "food" or "drug" pursuant to Section 15(b) and (c) 25 of the FTC Act, 15 U.S.C. § 55(b) and (c). As set forth below, 26 27 Levey, Ballen and the corporate defendants have engaged in such 28 unlawful practices in connection with the manufacturing,

-41-

1	advertising, packaging, labeling, promotion, offering for sale,					
2	sale, or distribution of Zymax, Millenex <u>ES</u> , Serotril and					
3	CartazyneDS.					
4	NINTH CAUSE OF ACTION					
5	False or	Unsubstantiated Claims for Zymax, Millenex <u>ES</u> , Serotril				
6		and Cartazyne <u>DS</u>				
7	(against Levey, Ballen and the corporate defendants)					
8	42.	Through the means described in Paragraphs 17, 20, 22				
9	and 23, L	evey, Ballen and the corporate defendants, on numerous				
10	occasions	, have represented that:				
11	a.	Zymax enables users to lose substantial amounts of				
12		weight in a short period of time without the need to				
13		increase exercise or reduce caloric intake;				
14	b.	Millenex <u>ES</u> enables users to lose substantial amounts of				
15		weight in a short period of time without the need to				
16		increase exercise or reduce caloric intake;				
17	c.	Serotril enables users to lose substantial amounts of				
18		weight in a short period of time without the need to				
19		increase exercise or reduce caloric intake;				
20	d.	Clinical studies prove that Zymax enables users to lose				
21		substantial amounts of weight in a short period of time				
22		without the need to increase exercise or reduce caloric				
23		intake;				
24	e.	Clinical studies prove that $Millenex \underline{ES}$ enables users to				
25		lose substantial amounts of weight in a short period of				
26		time without the need to increase exercise or reduce				
27		caloric intake;				
28	f.	Zymax has no side effects;				

I

-42-

MillenexES has no side effects; g. h. CartazyneDS cures arthritis; i. CartazyneDS rebuilds cartilage in human joints within 4 days; and 5 CartazyneDS is an effective alternative to joint j.

replacement surgery.

1

2

3

6

16

17

18

19

22

23

24

25

26

27

28

7 The representations set forth in Subparagraphs 42.a 43. 8 through 42.e are false or were not substantiated at the time the 9 representations were made. The representations set forth in 10 Subparagraphs 42.f through 42.j were not substantiated at the 11 time the representations were made. Therefore, the making of the 12 representations set forth in Paragraph 42 constitutes a deceptive 13 practice, and the making of false advertisements, in or affecting 14 commerce, in violation of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52. 15

TENTH CAUSE OF ACTION

Fictitious Product Endorsements and Testimonials (against Levey, Ballen and the corporate defendants) Through the means described in Paragraphs 17, 20, and 44.

20 22, Levey, Ballen and the corporate defendants, on numerous 21 occasions, have represented, expressly or by implication:

That "Dr. David Perry," "Dr. Jean-Paul Rappaport," and a. "Dr. Robert Aldan" are actual experts providing endorsements pertaining to the efficacy and the lack of side effects of Zymax, MillenexES, and Serotril, respectively; and

That persons depicted or described in the b. advertisements, including, but not limited to, "Barb

-43-

and Jim Zaine," "Nancy W.," "Alice Wilcox," in Zymax advertisements, "Don Jeffreys & Randy" and "Jim and Betty Wilson" in the Millenex<u>ES</u> advertisements, "Barabara" and "Dr. J." in the Serotril advertisements, and others not specifically identified, are existing persons whose actual and current opinions, findings, beliefs, and/or experiences are related in the advertisements.

1

2

3

4

5

6

7

8

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

9 45. The representations set forth in Paragraph 44 are
10 false. Therefore, the making of the representations set forth in
11 Paragraph 44 constitutes a deceptive practice, and the making of
12 false advertisements, in or affecting commerce, in violation of
13 Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52.

ELEVENTH CAUSE OF ACTION

False Demonstrations for Zymax and Cartazyne<u>DS</u> (against Levey, Ballen and the corporate defendants) 46. Through the means described in Paragraphs 17 and 23, Levey, Ballen and the corporate defendants, on numerous occasions, have represented, expressly or by implication:

- a. That the results shown in "before/after" photographs or visual images of a person's unclothed backside depicted in advertisements for Zymax accurately represent the performance of Zymax in causing substantial weight loss; and
 - b. That the results shown in "before/after" pictures, medical illustrations, and other visual images, including x-ray film, depicted in the advertisements for Cartazyne<u>DS</u> accurately represent the performance of

-44-

Cartazyne<u>DS</u> on human joints.

47. The representations set forth in Paragraph 46 are false. Therefore, the making of the representations set forth in Paragraph 46 constitutes a deceptive practice, and the making of false advertisements, in or affecting commerce, in violation of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52.

7

14

15

1

VII. CONSUMER INJURY

8 48. Consumers have suffered substantial monetary loss and
9 significant health risks as a result of Levey's, Ballen's and the
10 corporate defendants' unlawful acts or practices. Absent
11 injunctive relief by this Court, Ballen and the corporate
12 defendants are likely to continue to injure consumers and harm
13 the public interest.

VIII. CIVIL PENALTIES, REDRESS, INJUNCTIVE AND OTHER EQUITABLE RELIEF

16 49. For the five years preceding the filing of this 17 complaint, each dissemination by Levey, Bentley Myers, 18 Publisher's Data, and Nutritional Life of any advertisement or 19 promotional material in violation of the FTC Order, in one or 20 more of the ways described above, and each failure by Levey to 21 notify the Commission of his affiliation with a new business or 22 employment constitutes a separate violation for which plaintiff 23 seeks monetary civil penalties.

50. Sections 5(<u>1</u>) of the FTC Act, 15 U.S.C. §§ 45(<u>1</u>), as
modified by Section 4 of the Federal Civil Penalties Inflation
Adjustment Act of 1990, 28 U.S.C. § 2461, and Section 1.98(c) of
the Commission's Rules of Practice, 16 C.F.R. § 1.98(c),
authorizes this Court to award monetary civil penalties of not

-45-

1 more than \$11,000 for each such violation of the FTC Order that 2 occurs on or after November 20, 1996.

51. Sections 5(<u>1</u>) and 13(b) of the FTC Act, 15 U.S.C. §§ 4 45(<u>1</u>) and 53(b), authorize this Court to issue a permanent 5 injunction against Ballen and the corporate defendants violating 6 the FTC Order, the FTC Act, and to grant ancillary relief, 7 including consumer redress, disgorgement, and restitution to 8 prevent and remedy any violations of any provision of law 9 enforced by the Commission.

10 52. This Court, in the exercise of its equitable 11 jurisdiction, may award other ancillary relief to remedy the 12 injury caused by Levey's, Ballen's and the corporate defendants' 13 violations of the law.

14

IX. PRAYER FOR RELIEF

15 WHEREFORE, plaintiff requests that this Court, pursuant to 16 15 U.S.C. §§ 45(a), $45(\underline{1})$, 53(b), and 56(a), and pursuant to this 17 Court's own equitable powers:

Enter judgment against defendants Lisa Levey, in her
 capacity as personal representative of the Estate of Michael
 Levey, Ballen and the corporate defendants and in favor of
 plaintiff for each violation alleged in this Complaint;

22 2. Award plaintiff monetary civil penalties from defendant
23 Lisa Levey, in her capacity as personal representative of the
24 Estate of Michael Levey, and the corporate defendants for each
25 violation of the FTC Order alleged in this Complaint;

26 3. Permanently enjoin the corporate defendants from
27 violating the FTC Order issued in FTC Docket No. C-3459;
28 4. Permanently enjoin Ballen and the corporate defendants

-46-

1 from engaging in, or assisting others engaged in, violations of 2 the FTC Act;

5. Award such relief as the Court finds necessary to redress injury to consumers resulting from Levey's, Ballen's and the corporate defendants' violations of the FTC Order and the FTC Act; including, but not limited to, rescission of contracts, the refund of monies paid, and the disgorgement of ill-gotten monies; 6. Award plaintiff the costs of bringing this action, as well as such other and additional relief as the Court may determine to be just and proper; and 7. Grant such equitable relief as the Court may determine to be just and proper.

1	DATED:	Respectfully Submitted
2 3		DEBRA W. YANG United States Attorney for the Central District of California
4 5		VINCE FARHAT Assistant U.S. Attorney
6		PETER D. KEISLER
7		Assistant Attorney General Civil Division U.S. Department of Justice
8 9		EUGENE M. THIROLF Director
9 10		Office of Consumer Litigation
11		
12		RICHARD N. GOLDBERG Trial Attorney
13		OF COUNSEL:
14 15		ELAINE D. KOLISH Associate Director
16		for Enforcement Federal Trade Commission
17		JONI LUPOVITZ Assistant Director
18 19		for Enforcement Federal Trade Commission
20		ROBIN M. RICHARDSON Attorneys
21		Federal Trade Commission
22		
23		
24		
25		
26		
27		
28		

1			INDEX OF EXHIBITS
2	Exhibit	Α.	FTC Administrative Complaint
3	Exhibit	В.	FTC Administrative Order
4	Exhibit	C-1.	March 2002 edition of "Plastic Surgery Magazine" (Zymax)
5 6	Exhibit	C-2.	February-March 2001 edition of "Plastic Surgery Magazine" (Zymax)
7 8	Exhibit	C-3.	February 2000 edition of "Plastic Surgery Magazine" (Zymax)
8 9	Exhibit	D.	Summer 2001 edition of "Diet News" (Millenex <u>ES</u>)
9 10	Exhibit	E-1.	"Special Edition" of "Serotril Sciences" Vol 3 - No. 5 (Serotril)
11 12	Exhibit	E-2.	Winter/Spring 1999 edition of "Serotril Sciences" Vol 2 - No. 4 (Serotril)
	Exhibit	E-3.	Serotril brochure
13	Exhibit	F-1.	Cartazyne <u>DS</u> brochure
14 15	Exhibit	F-2.	"Longevity Sciences Report" Vol. 3 No. 4 (Cartazyne <u>DS</u>)
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			
			-49-